The invention relates to mixtures having: components (a) having at least one fragrance of the formula (I) ##STR00001## where R1=OCR2, CH.sub.2OR3, C1-C8 open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, with R2=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 2-10 C atoms, with R3=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 1-8 C atoms, and components (b) having at least one fragrance, different from the fragrances of component a,
characterized in that the weight ratio of all components (a) to all components (b) is from 1:10 to 1:10000.

The invention relates to mixtures having: components (a) having at least one fragrance of the formula (I) ##STR00001## where R1=OCR2, CH.sub.2OR3, C1-C8 open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, with R2=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 2-10 C atoms, with R3=an open-chain or branched aliphatic radical, optionally substituted and/or unsaturated, having 1-8 C atoms, and components (b) having at least one fragrance, different from the fragrances of component a,
characterized in that the weight ratio of all components (a) to all components (b) is from 1:10 to 1:10000.

The present invention provides a compound represented by general formula (1). ##STR00001##
(In the formula, R.sup.1 represents an alkyl group having 2 to 9 carbon atoms, an alkenyl group having 2 to 9 carbon atoms, a cyclic alkyl group having 3 to 10 carbon atoms which may have a substituent, or a phenyl group which may have a substituent; R.sup.2 represents an alkyl group having 1 to 3 carbon atoms; R.sup.3 to R.sup.5 independently represent a hydrogen atom, or an alkyl group having 1 to 3 carbon atoms; R.sup.6 represents an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 2 to 5 carbon atoms, a cyclic alkyl group having 3 to 10 carbon atoms which may have a substituent, or an alkoxy group having 1 to 5 carbon atoms; n represents 0 or 1; and the wavy line represents a cis form, a trans form or a mixture of a cis form and a trans form.)

The present invention provides a compound represented by general formula (1). ##STR00001##
(In the formula, R.sup.1 represents an alkyl group having 2 to 9 carbon atoms, an alkenyl group having 2 to 9 carbon atoms, a cyclic alkyl group having 3 to 10 carbon atoms which may have a substituent, or a phenyl group which may have a substituent; R.sup.2 represents an alkyl group having 1 to 3 carbon atoms; R.sup.3 to R.sup.5 independently represent a hydrogen atom, or an alkyl group having 1 to 3 carbon atoms; R.sup.6 represents an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 2 to 5 carbon atoms, a cyclic alkyl group having 3 to 10 carbon atoms which may have a substituent, or an alkoxy group having 1 to 5 carbon atoms; n represents 0 or 1; and the wavy line represents a cis form, a trans form or a mixture of a cis form and a trans form.)

A catalytic process for the methoxycarbonylation of olefins where formic acid is the CO source. The process includes the steps of forming a reaction mixture where methanol and formic acid are added at a volume ratio in the range from 1.55:0.45 to 1.1:09. The methanol-formic acid ratio enhances both the rate of conversion and methyl ester yield ether produced. The catalysts used is a palladium/benzene-base diphosphine ligand complex.

A catalytic process for the methoxycarbonylation of olefins where formic acid is the CO source. The process includes the steps of forming a reaction mixture where methanol and formic acid are added at a volume ratio in the range from 1.55:0.45 to 1.1:09. The methanol-formic acid ratio enhances both the rate of conversion and methyl ester yield ether produced. The catalysts used is a palladium/benzene-base diphosphine ligand complex.

An ester of beta-hydroxy butyrate or derivate esterfied with an amino acid or fatty acid used as an oral supplement.

An ester of beta-hydroxy butyrate or derivate esterfied with an amino acid or fatty acid used as an oral supplement.

Provided are compounds, including compositions comprising the same, which function to recruit various target proteins (e.g., client proteins of 14-3-3 proteins) to an E3 ubiquitin ligase enzyme for ubiquitination and subsequent degradation, and methods of using the same.

Provided are compounds, including compositions comprising the same, which function to recruit various target proteins (e.g., client proteins of 14-3-3 proteins) to an E3 ubiquitin ligase enzyme for ubiquitination and subsequent degradation, and methods of using the same.